BioSyent Releases Results for Q1 2018
TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three months ended March 31, 2018. Key highlights include: First quarter (Q1) 2018 Net Revenues of $4,447,147 increased by 16% versus Q1 2017 Q1 2018 Canadian Pharmaceutical Net Revenues of $3,765,638 increased by 12% versus Q1 2017 and International Pharmaceutical Net Revenues of $565,841 increased by 90% versus Q1 2017 Q1 2018 EBITDA 1 of $1,477,767 increased by 24% versus Q1 2017 Q1 2018 Net Income After Tax (NIAT) of $1,143,130 increased by 27% versus Q1 2017 Q1 2018 NIAT percentage to Net Revenues of 26% compares to 24% in Q1 2017 Q1 2018 Fully Diluted EPS of $0.08 was $0.02 higher than Q1 2017 Fully Diluted EPS of $0.06 Fully Diluted EPS for the Trailing Twelve Months ended March 31, 2018 was $0.38 as compared to $0.29 for the Trailing Twelve Months ended March 31, 2017 As at March 31, 2018, the Company had cash, cash equivalents,